Is Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Supernus Pharmaceuticals, Inc. at current levels.
Qelbree's non-stimulant ADHD franchise plus ONAPGO's Parkinson's launch turn a sleepy specialty pharma into a $1B+ CNS cash machine.
Where SUPN is headed
By the back half of 2027, Supernus looks nothing like the legacy specialty pharma the market still prices it as. Qelbree, the non-stimulant ADHD product, is on track to exit 2026 at a $400M+ annualised run-rate and pushing toward $600M by 2028 as the broader ADHD market keeps shifting away from controlled stimulants. The DEA scheduling fight on amphetamines, the Adderall shortage hangover, and the gradual cultural pivot among parents away from putting eight-year-olds on Schedule II compounds are all tailwinds Supernus already monetises. Meanwhile ONAPGO, the apomorphine subcutaneous pump for advanced Parkinson's, was approved in 2025 and is in the early innings of a launch into a market AbbVie's Vyalev is also building. Two devices, two big specialty pharma sales forces, both educating neurologists on continuous infusion. That is how categories get made.
Read the full Compass Direction on SUPN
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $48.21).
See the full SUPN analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Supernus Pharmaceuticals, Inc. at current levels. Qelbree's non-stimulant ADHD franchise plus ONAPGO's Parkinson's launch turn a sleepy specialty pharma into a $1B+ CNS cash machine.
What is SUPN's Compass Score?
Supernus Pharmaceuticals, Inc. scores 78/100 on Alexandria's Compass, placing it in the "True North" tier. Scores blend eight factors and update weekly.
What is the price target for SUPN?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the SUPN page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.